Meet an M2D2 $200K Challenger: Fairbanks Pharmaceuticals

Fairbanks Pharmaceuticals is a finalist in the 7th annual M2D2 $200K Challenge.

Alan Schneyer of Fairbanks Pharmaceuticals

Introducing Fairbanks Pharmaceuticals, one of 20 medtech startups chosen as finalists in the 7th annual M2D2 $200K Challenge. CEO Alan Schneyer explains their innovation and shares the story of its development.

What is the innovation you’ve entered in the M2D2 $200K Challenge?

Fairbanks Pharmaceuticals is developing a novel treatment for type 1 and type 2 diabetes that addresses the underlying cause of the disease. Continue reading

Meet an M2D2 $200K Challenge Finalist: Integrated Medical Sensors

Integrated Medical Sensors is a finalist in the 7th annual M2D2 $200K Challenge.

Muhammad Mujeeb- U-Rahman of Integrated Medical Sensors

Integrated Medical Sensors is one of 20 medtech startups chosen as finalists in the 7th annual M2D2 $200K Challenge. CEO Muhammad Mujeeb-U-Rahman recounts the journey of their innovation from inspiration to development to the Challenge finals.

What is the innovation you’ve entered in the M2D2 $200K Challenge?

IMS has developed the world’s smallest wireless glucose sensor that requires no calibration, is user-insertable, and works for 30 days or longer.  Continue reading

Meet an M2D2 $200K Finalist: Advanced Silicon Group

Advanced Silicon Group is a finalist in the 7th Annual M2D2 $200K Challenge.

ASG co-founders Marcie Black and Bill Rever

Advanced Silicon Group (ASG) is one of 20 medtech startups chosen as finalists in the 7th annual M2D2 $200K Challenge. CEO Marcie Black told us the story behind their innovation and shared their vision for its future. 

What is the innovation you’ve entered in the M2D2 $200K Challenge?

ASG is enabling drug developers to measure the concentration of biomarkers in patients’ blood, giving an early indicator in clinical trials. Continue reading

Meet an M2D2 $200K Challenge Finalist: Versatope

Versatope is a finalist in the 7th Annual M2D2 $200K Challenge

Clockwise from top left: Christopher Locher, CEO/Co-Founder; Mark Duffy, CFO/COO; Kien Nguyen, Senior Director, Microbiology; David Putnam, Co-Founder; Matthew DeLisa, Co-Founder; Ly Phan, SVP, Portfolio Management & Preclinical Development

Meet Versatopeone of 20 medtech startups chosen as finalists in the 7th annual M2D2 $200K Challenge. SVP Ly Phan described their innovation and shared the story behind its inspiration and development.

What is the innovation you’ve entered in the M2D2 $200K Challenge?

An immuno-therapeutic and vaccine delivery platform made from probiotic exosomes (extracellular vesicles)—designed by nature and customized by Versatope to deliver immunity. Continue reading

Meet an M2D2 $200K Finalist: MedKairos

MedKairos is a finalist in the 7th annual M2D2 $200K Challenge.

Andy Kozminski and Michael Moore of MedKairos

MedKairos is one of 20 medtech startups chosen as finalists in the 7th annual M2D2 $200K Challenge. Co-founder Michael Moore explained their innovation and the story behind its inspiration and development.

What is the innovation you’ve entered in the M2D2 $200K Challenge?

One out of five biopsies fails to return a diagnosis. Our technology intervenes during the procedure, so patients will only undergo the procedure once. Continue reading

Meet an M2D2 Finalist: MAG Optics

MAG Optics is a finalist in the 7th annual M2D2 $200K Challenge.

Geeta Singh of MAG Optics

MAG Optics is one of 20 finalists in the 7th annual M2D2 $200K ChallengeGeeta Singh, Co-founder and Chief Business Officer, shares the story of their innovation.

What is the innovation you’ve entered in the M2D2 $200K Challenge?

MAG Optics is pioneering an intra-corneal implant, MAGarcs, that is the first patient-centric corneal shape-changing platform to address keratoconus, a rare degenerative disease characterized by a cone-shaped cornea.   Continue reading

Innovation in Spine Surgery—Evidence-Based Medicine. Attend the panel discussion at UMass Medical on April 6.

The panel discussion will focus on innovation in spine surgery to improve clinical outcomes. Considering the complex spinal pathology, spine surgeons leverage different technologies and techniques to achieve a safe and efficacious clinical outcome. Researchers and clinicians with a multi-disciplinary background will share their scientific data with all spine specialists. Continue reading

Meet an M2D2 Finalist: AMProtection

AMProtection is a finalist in the M2D2 $200K Challenge.

Dr. Lindsey Lozeau and Todd E. Alexander of AMProtection

Introducing AMProtection, one of 20 medtech startups chosen as finalists in the 7th annual M2D2 $200K Challenge. Co-founder Todd Alexander shared the story of their innovation and its development so far. 

What is the innovation you’ve entered in the M2D2 $200K Challenge?

AMProtection provides platform antimicrobial coatings to prevent medical device-associated infections without promoting bacterial resistance. Continue reading

Meet an M2D2 Finalist: Drug Free Therapeutix

Drug Free Therapeutix is a finalist in the 7th annual M2D2 $200k Challenge.

Clockwise from top left: Stephen Hourigan, CEO/Co-Founder; John Ward, President/Co-Founder; Matthew Ward, CSO/Co-Founder; Shreyas Sen, CTO/Co-Founder

Meet Drug Free Therapeutix, one of 20 medtech startups chosen as finalists in the 7th annual M2D2 $200K Challenge. Co-founder and CSO Matthew Ward took us inside the development of their innovation. 

What is the innovation you’ve entered in the M2D2 $200K Challenge?

DFTx empowers next-generation bioelectronics for pain and other conditions through machine learning and human body communication technology. Continue reading

Meet an M2D2 Finalist: 3D Tumor Targeting

Huanchen Li of 3D Tumor Targeting is a finalist in the 7th Annual M2D2 $200K Challenge.

Huanchen Li of 3D Tumor Targeting

3D Tumor Targeting is one of 20 medtech startups chosen as finalists in the 7th annual M2D2 $200K Challenge. Founder Huanchen Li described his innovation and shared the story behind it.

What is the innovation you’ve entered in the M2D2 $200K Challenge?

With external magnets, we manipulate in vivo diamagnetic nanoparticles in a 3D manner into tumors, then heat the nanoparticles to destroy the tumors. Continue reading